| Adela' Marie Narcisse, MD | |
|
105 Medical Center Dr, Suite #303, Slidell, LA 70461-5544 | |
| (985) 639-3777 | |
| (985) 639-3770 |
| Full Name | Adela' Marie Narcisse |
|---|---|
| Gender | Female |
| Speciality | Obstetrics & Gynecology |
| Location | 105 Medical Center Dr, Slidell, Louisiana |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891972410 | NPI | - | NPPES |
| 1138932 | Medicaid | LA | |
| 00877769 | Other | MS | MEDICAID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | MD.201941 (Louisiana) | Primary |
| 207V00000X | Obstetrics & Gynecology | 063272 (Georgia) | Secondary |
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
| Entity Name | St Tammany Parish Hospital Service District No 1 |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598798597 PECOS PAC ID: 0749273761 Enrollment ID: O20051102000003 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
| Entity Name | Baton Rouge General Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215199724 PECOS PAC ID: 4082600077 Enrollment ID: O20081121000299 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
| Entity Name | East Jefferson Physicians Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922293372 PECOS PAC ID: 4587660402 Enrollment ID: O20090127000299 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
| Entity Name | Obhg Louisiana Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639567316 PECOS PAC ID: 9234443250 Enrollment ID: O20150805006718 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Adela' Marie Narcisse, MD 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Adela' Marie Narcisse, MD 105 Medical Center Dr, Suite #303, Slidell, LA 70461-5544 Ph: (985) 639-3777 |
News Archive
A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology.
Kindred Healthcare, Inc. today provided its estimate of the revenue effect of proposed rate changes to Medicare Part B therapy services included in the proposed Medicare Physician Fee Schedule rule. The proposed rule was released by the Centers for Medicare and Medicaid Services ("CMS") on June 25. The proposed rule is subject to a 60-day public comment period and is scheduled to become effective January 1, 2011.
Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.
Idaho Technology, Inc. has signed a licensing agreement with E. I. du Pont de Nemours and Company acting through its DuPont Qualicon Business covering reagents or methods using SYBR® Green I technology and post-PCR melting curve analysis.
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.
› Verified 3 days ago
Dr. Santo J Paniello, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1850 Gause Blvd E, Slidell, LA 70461 Phone: 985-639-3777 Fax: 985-661-3512 | |
Dr. Melissa Welch Smith, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1150 Robert Blvd, Ste.360, Slidell, LA 70458 Phone: 985-781-4848 Fax: 985-781-4850 | |
James Sibley Holmes, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 107 Mary Ellen Dr, Slidell, LA 70460 Phone: 985-643-4214 Fax: 985-643-4214 | |
Dr. Robert J Muller, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 105 Smart Pl, Slidell, LA 70458 Phone: 985-641-2100 Fax: 985-641-2152 | |
Blake C. Landry, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2365 Gause Blvd E Ste E, Slidell, LA 70461 Phone: 985-643-1194 Fax: 985-643-8869 | |
Dr. Jason H Collins, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 2250 Gause Blvd E, Ste 200, Slidell, LA 70461 Phone: 985-649-0325 Fax: 985-643-2820 | |
Dr. Diana K. Clavin, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1150 Robert Blvd, Suite 360, Slidell, LA 70458 Phone: 985-781-4848 Fax: 985-781-4850 |